The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Adipokines as Drug Targets in Diabetes and Underlying Disturbances
Open accessAbstract
Diabetes and obesity are worldwide health problems. White fat dynamically participates in hormonal and inflammatory regulation. White adipose tissue is recognized as a multifactorial organ that secretes several adipose-derived factors that have been collectively termed “adipokines.” Adipokines are pleiotropic molecules that gather factors such as leptin, adiponectin, visfatin, apelin, vaspin, hepcidin, RBP4, and inflammatory cytokines, including TNF and IL-1 β, among others. Multiple roles in metabolic and inflammatory responses have been assigned to these molecules. Several adipokines contribute to the self-styled “low-grade inflammatory state” of obese and insulin-resistant subjects, inducing the accumulation of metabolic anomalies within these individuals, including autoimmune and inflammatory diseases. Thus, adipokines are an interesting drug target to treat autoimmune diseases, obesity, insulin resistance, and adipose tissue inflammation. The aim of this review is to present an overview of the roles of adipokines in different immune and nonimmune cells, which will contribute to diabetes as well as to adipose tissue inflammation and insulin resistance development. We describe how adipokines regulate inflammation in these diseases and their therapeutic implications. We also survey current attempts to exploit adipokines for clinical applications, which hold potential as novel approaches to drug development in several immune-mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin and the regulation of body weight in mammals
Friedman, J. M., & Halaas, J. L. (1998) · Nature · doi:10.1038/27376 · Cited by 5,405
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., & Spiegelman, B. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117936 · Cited by 3,543
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230 · cited 1×
“Because TNF is secreted by the adipose tissue in obese mice and humans, TNF is also considered an adipokine [98, 99].”
BackgroundHepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B. (2005) · Nature · doi:10.1038/nature03711 · Cited by 2,086
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Adipose Tissue as an Endocrine Organ
Ahima, R. S., & Flier, J. S. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00301-5 · Cited by 1,608
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects
Graham, T. E., Yang, Q., Blüher, M., Hammarstedt, A., Ciaraldi, T. P., Henry, R. R., Wason, C. J., Oberbach, A., Jansson, P.-A., Smith, U., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054862 · Cited by 1,319
The weight of leptin in immunity
Cava, A. L., & Matarese, G. (2004) · Nature Reviews Immunology · doi:10.1038/nri1350 · Cited by 927 · cited 1×
“TheWorldHealthOrganization predicts that 3 billion adults will be either overweight or obese by 2015 [1].”
BackgroundA Membrane Receptor for Retinol Binding Protein Mediates Cellular Uptake of Vitamin A
Kawaguchi, R., Yu, J., Honda, J., Hu, J., Whitelegge, J., Ping, P., Wiita, P., Bok, D., & Sun, H. (2007) · Science · doi:10.1126/science.1136244 · Cited by 836
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
STAT3 Is Required for IL-6-gp130–Dependent Activation of Hepcidin In Vivo
Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C., & Trautwein, C. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.018 · Cited by 315
The hepatic apelin system: A new therapeutic target for liver disease†
Principe, A., Melgar‐Lesmes, P., Fernández‐Varo, G., del Arbol, L. R., Ros, J., Morales‐Ruiz, M., Bernardi, M., Arroyo, V., & Jiménez, W. (2008) · Hepatology · doi:10.1002/hep.22467 · Cited by 127
Hepcidin antagonists for potential treatments of disorders with hepcidin excess
Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., & Arosio, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00086 · Cited by 124
Hepcidin Activation During Inflammation: Make It STAT
Fleming, R. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.049 · Cited by 36
Cited by
Adipose tissue in control of metabolism
Luo, L., & Liu, M. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0211 · Cited by 693
The macrophage switch in obesity development
Castoldi, A., Naffah de Souza, C., Câmara, N. O. S., & Moraes-Vieira, P. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00637 · Cited by 575
Self-citationExercise modulates oxidative stress and inflammation in aging and cardiovascular diseases
Sallam, N., & Laher, I. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7239639 · Cited by 334
“Exercise training/physical activity also induces the release of adiponectin from adipose tissues [192–197]; adiponectin exerts antiapoptotic, anti-inflammatory, and antioxidative activities [198, 199].”
BackgroundLeptin, cardiovascular diseases and type 2 diabetes mellitus
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.40 · Cited by 285
Metadata
- Authors
- Andrade-Oliveira, V., Câmara, N. O. S., & Moraes-Vieira, P. M.
- Venue
- Journal of Diabetes Research
- Publisher
- Hindawi Limited
- Published
- 2015
- Volume
- 2015
- Pages
- 1-11
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W2051835216
- Cited by
- 166
- References
- 20
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.